New York Post
02 Aug 2026, 21:40 UTC · 1h ago
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
New York Post
02 Aug 2026, 21:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AstraZeneca and Bristol Myers Squibb have held talks regarding a potential merger that would create a pharmaceutical group valued at nearly $400 billion. — A mega-merger of this scale would trigger significant price volatility for both tickers and potentially spark a consolidation wave in the pharma sector.
+0.80AstraZeneca's second-quarter results show continued strong growth in cancer treatments ($25B in 2025 sales) and cardiovascular/renal/metabolism treatments ($12B). — Strong organic growth in high-margin specialty drug areas supports a higher valuation and makes the company a more attractive merger partner.
+0.30AstraZeneca previously planned a direct US listing to capitalize on higher US market valuations while maintaining its London listing. — This indicates a strategic shift toward US capital markets, which generally offer higher multiples for biotech and pharma.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Reporting strong growth in cancer and rare disease drugs and potential for a massive strategic merger.
Mentioned as a potential partner in a $400 billion megadeal that could create one of the world's largest pharmaceutical groups.
Mentioned as a rival that has been outperformed by AstraZeneca's share price growth.
Mentioned only in the historical context of a failed takeover attempt from a decade ago.
[mutual] The article describes Bristol Myers Squibb as a US rival to AstraZeneca.
[mutual] GSK is identified as a main British rival to AstraZeneca.
[mutual] Pfizer is described as a larger US rival to AstraZeneca.
[mutual] The companies have held talks on a potential tie-up and combination deal.
[a_to_b] Pfizer previously attempted a takeover of AstraZeneca.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
3h ago
